L to R: Florence Allouche Ghrenassia, PharmD, President, SparingVision; Frédérique Vidal, French Minister of Higher Education, Research and Innovation; José-Alain Sahel, MD, Co-Founder, SparingVision and Fondation Voir & Entendre; David Brint, Chairman, Foundation Fighting Blindness; and Laure Reinhardt, Deputy CEO, Bpifrance
A newly established French company, SparingVision, has won the 2017 i-Lab Grand Prize recognizing new and innovative companies. The i-Lab competition is organized by the French Ministry of Higher Education, Research and Innovation and Bpifrance (BPI).
The Foundation Fighting Blindness (FFB) today announced $6 million in new research funding across a spectrum of potential preventions, treatments and cures for inherited retinal diseases including retinitis pigmentosa and macular degeneration.
However, researchers identify a potentially powerful endpoint for evaluating emerging therapies in future studies.
The Foundation Fighting Blindness (FFB), the world’s leading private funder of research aimed at preventing, treating and curing blindness caused by inherited retinal diseases hosted its annual Fashion and Finance Ball on Tuesday, May 16 at New York’s Plaza Hotel. To date, the dinner has raised $425,000 for inherited retinal disease research and donations are continuing to be made.
ProQR, a biotechnology company in the Netherlands, has received authorization from the U.S. Food and Drug Administration to start a Phase I/II clinical trial for its therapy known as QR-110, which is being developed for Leber congenital amaurosis type 10 (LCA 10). The genetic retinal condition causes severe vision loss in children.
The Foundation Fighting Blindness (FFB), the world’s leading private funder of research aimed at preventing, treating and curing blindness caused by inherited retinal diseases will hold its Fashion and Finance Ball on Tuesday, May 16 at New York’s Plaza Hotel. A cocktail reception and silent auction will open the evening at 6:00 p.m.; the dinner and awards program will begin at 7:00 p.m.